SCHEMBL17560970

SCHEMBL17560970

Nc1nc(NN=Cc2cc(O)ccc2O)cc(NN=Cc2cc(O)ccc2O)n1.O=Cc1cc(O)ccc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 12/20 0.44
▸ MEN1 O00255 11/20 0.44
▸ GAA P10253 6/20 0.44
▸ POLB P06746 5/20 0.44
▸ NPC1 O15118 4/20 0.43
▸ NCOA1 Q15788 1/20 0.42
▸ NCOA3 Q9Y6Q9 1/20 0.42
▸ AMY1A P0DUB6 1/20 0.42
▸ MAPT P10636 8/20 0.41
▸ KDM4E B2RXH2 7/20 0.41
▸ LMNA P02545 7/20 0.41
▸ HTT P42858 5/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ HSP90AA1 P07900 2/20 0.41
▸ TDP1 Q9NUW8 3/20 0.40
▸ L3MBTL1 Q9Y468 3/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ MGAM O43451 2/20 0.40
▸ TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17560967 1.00 KMT2A (0.44) KMT2AMEN1GAAPOLBNPC1
SCHEMBL19449736 0.93 KMT2A (0.49) KMT2AMEN1GAAPOLBNPC1
SCHEMBL17560842 0.82 MEN1 (0.62) KMT2AMEN1GAAPOLBNPC1
SCHEMBL17560848 0.82 MEN1 (0.62) KMT2AMEN1GAAPOLBNPC1
SCHEMBL19449748 0.80 KMT2A (0.66) KMT2AMEN1GAAPOLBNPC1
SCHEMBL17560799 0.79 GAA (0.52) KMT2AMEN1GAAPOLBNPC1
SCHEMBL17560796 0.79 GAA (0.52) KMT2AMEN1GAAPOLBNPC1
SCHEMBL19434700 0.78 KMT2A (0.59) KMT2AMEN1GAAPOLBNPC1
SCHEMBL19434701 0.78 KMT2A (0.59) KMT2AMEN1GAAPOLBNPC1
SCHEMBL16224338 0.75 SMN1; SMN2 (0.57) KMT2AMEN1GAAPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566012-B2 Methods for treating protozoan infections NEOCULI PTY LTD (AU) 2023-01-31 — — US claimed
US-20210009552-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2021-01-14 — — US claimed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 — — US claimed
EP-3188722-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS Neoculi Pty Ltd (AU) 2017-07-12 — — EP claimed
WO-2016033635-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2016-03-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566012-B2 Methods for treating protozoan infections DPM1, ABCB11, PIGS KMT2A 2912/4885MEN1 504/4885GAA 231/4885
US-20210009552-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS KMT2A 2912/4885MEN1 504/4885GAA 231/4885
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS KMT2A 2912/4885MEN1 504/4885GAA 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback